Brandon Capital
Deal focus: Australia’s ENA hits COVID-19 in the nose
Australian investors see hope in ENA Respiratory, a nasal spray specialist aiming to complement global COVID-19 vaccine programs with an immune system-boosting product
Australia COVID-19 nasal spray maker raises $25m
ENA Respiratory, an Australian biotech company developing a nasal spray for the prevention of COVID-19, has raised A$32 million ($25 million) with support from local venture capital investor Brandon Capital.
Medical devices: Proceed with caution
Medical devices has become a difficult place to invest but potentially all the more rewarding for those willing to take the plunge. Asia is in a prime position globally
Brandon invests $6m in Australia medtech company
Brandon Capital has committed A$7.7 million ($6 million) to Australian medical technology developer Global Kinetics.
Allergan to acquire Australia's VC-backed Elastagen
Allergan, a US-listed pharmaceutical company and the owner of Botox cosmetic injectable products, has agreed to acquire Elastagen, an Australian skin treatment developer backed by a number of VCs, in a deal worth up to $260 million.
Australian VCs invest $16m in domestic drug developer
Australian VC investors Brandon Capital and Uniseed have committed $16 million to Que Oncology, a clinical-stage drug development company established by the University of Queensland (UQ) and US-based Emory University.
Australia VC: Meet the neighbors
Australia’s growing technology sector is set to benefit from long-term socioeconomic trends in Asia. Success will depend on both operational tenacity and a fundamental shift in expansion philosophy
Three GPs chosen to manage Australia biomedical fund
OneVentures, Brandon Capital and BioScience Managers have been selected to manage the Australian government’s A$500 million ($375 million) Biomedical Translation Fund (BTF).
Australia VC: Interesting times
AirTree Ventures' successful fundraise underlines the growth interest in Australian venture capital, but the superannuation funds have yet to prove themselves to be a consistent source of capital
Australia's Brandon Capital expands into New Zealand
Australian life sciences-focused VC firm Brandon Capital has expanded the mandate of its third Medical Research Commercialization Fund (MRCF) to include New Zealand.
Australian LPs and domestic VC: Toe in the water
Australian super funds are showing renewed interests in domestic venture capital, supporting firms that offer flexible structures with co-investment opportunities. Can this approach work for all GPs?
Novartis buys VC-backed Australian drug developer Spinifex
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Fund focus: Brandon secures super fund support
With A$78 billion ($61 billion) in assets, AustralianSuper is said to struggle to make fund commitments of less than A$150 million. Yet it is one of several superannuation funds backing Brandon Capital’s latest life sciences VC vehicle, which has closed...
Australian medical research fund backs antibody start-up
Solvanix, an Australian early-stage biotech company that has developed a technology for improving drug stability, has received A$2 million ($1.6 million) in seed funding from the Medical Research Commercialization Fund (MRCF).
Osprey Medical plans to raise $20m in Australia listing
US-based Osprey Medical hopes to raise $20 million through a public listing in Australia next month. The medical device company submitted its prospectus to the stock exchange this week.